In the last two weeks, Sarepta has been threatened by the FDA with having its drug pulled, refused to do so, then capitulated, and then won a reversal by the regulator. We'll talk with R.W. Baird analyst Brian Skorney, who has followed the company's ups and downs for years, and what this latest twist tells us about the company's future, how this FDA is operating, and the power of patient and political pressure.